Retatrutide is the most powerful weight loss drug ever tested in clinical trials. This triple-action injectable from Eli Lilly targets three hormone receptors simultaneously — producing results that rival bariatric surgery. Here's everything Malaysian patients need to know about retatrutide in 2026, including when it might arrive here and what it could cost.
Key Takeaways
- Retatrutide is a first-in-class triple agonist targeting GLP-1, GIP, and glucagon receptors — developed by Eli Lilly
- Phase 2 results: Up to 24.2% body weight loss at the highest dose (12 mg) over 48 weeks, published in the New England Journal of Medicine
- Phase 3 TRIUMPH trials: Ongoing across 5 indications including obesity, type 2 diabetes, and MASH (fatty liver disease). Initial data readouts expected late 2026
- Projected Malaysia price: RM2,500–4,500/month based on the pricing trajectory of Mounjaro
- Malaysia availability: Estimated 2029–2030, following FDA approval (expected late 2027–2028) and NPRA registration
- Not yet approved anywhere — do not buy from online sellers claiming to stock retatrutide
Medical Disclaimer: Retatrutide is an investigational drug not yet approved by any regulatory authority worldwide. This article is for informational purposes only and reflects data from published clinical trials. Do not attempt to obtain or use unapproved medications. Always consult a qualified healthcare professional.
What Is Retatrutide?
Retatrutide (development code LY3437943) is a triple hormone receptor agonist — the first drug ever to simultaneously activate three key metabolic pathways. It's being developed by Eli Lilly, the same company behind Mounjaro (tirzepatide).
To understand why retatrutide is generating so much excitement, it helps to see the evolution of this drug class:
| Generation | Drug | Targets | Best Weight Loss |
|---|---|---|---|
| 1st Gen | Ozempic/Wegovy (semaglutide) | GLP-1 only | ~15% |
| 2nd Gen | Mounjaro (tirzepatide) | GLP-1 + GIP | ~22.5% |
| 3rd Gen | Retatrutide | GLP-1 + GIP + Glucagon | ~24.2% |
Each new generation has delivered a measurable leap in efficacy. Retatrutide represents the most dramatic weight loss ever achieved by a pharmaceutical intervention.
The Three Mechanisms of Action
Here's what each receptor target does and why the combination is so powerful:
- GLP-1 (glucagon-like peptide-1) receptor agonism — The proven foundation. Reduces appetite, slows gastric emptying, improves insulin secretion. This is the same mechanism behind Ozempic and Wegovy.
- GIP (glucose-dependent insulinotropic polypeptide) receptor agonism — Enhances insulin sensitivity, improves fat metabolism, and may amplify the effects of GLP-1. This is the second mechanism in Mounjaro.
- Glucagon receptor agonism — The game-changer. This is entirely new. Glucagon activation increases your basal energy expenditure (you burn more calories at rest), promotes lipolysis (fat breakdown), and may dramatically reduce liver fat.
Why the Glucagon Component Matters
GLP-1 drugs work primarily by making you eat less. The glucagon component in retatrutide adds something fundamentally different — it makes your body burn more. This addresses both sides of the energy balance equation:
- Energy in (reduced by GLP-1 and GIP — appetite suppression, slower digestion)
- Energy out (increased by glucagon — higher resting metabolic rate, enhanced fat oxidation)
This dual approach may also help counteract metabolic adaptation — the well-documented phenomenon where your body reduces calorie expenditure as you lose weight, which is a major reason diets and even some medications plateau.
Additionally, glucagon receptor activation has shown remarkable effects on liver fat reduction, making retatrutide a potential breakthrough treatment for MASH (metabolic dysfunction-associated steatohepatitis), formerly called NASH. This is especially relevant in Malaysia, where non-alcoholic fatty liver disease affects an estimated 25–30% of adults.
Phase 2 Clinical Trial Results
The Phase 2 trial results for retatrutide were published in the New England Journal of Medicine in June 2023 (Jastreboff et al.). The study was a randomised, double-blind, placebo-controlled trial enrolling 338 adults with obesity (BMI ≥30 or ≥27 with comorbidities) across multiple doses over 48 weeks.
Weight Loss by Dose Group
| Dose Group | Mean Weight Loss (48 Weeks) | % Achieving ≥15% Loss |
|---|---|---|
| Placebo | 2.1% | — |
| 1 mg | 8.7% | 29% |
| 4 mg (escalated) | 17.1% | 67% |
| 4 mg (fixed) | 22.8% | 75% |
| 8 mg (escalated) | 22.1% | 81% |
| 8 mg (fixed) | 25.4% | 83% |
| 12 mg (escalated) | 24.2% | 93% |
At the highest evaluated dose (12 mg with escalation), participants lost an average of 24.2% of their body weight — and 93% of participants lost at least 15%. For a 100 kg person, that's 24 kg lost in under a year.
The weight loss curves had not yet plateaued at 48 weeks, suggesting that continued treatment could yield even greater losses. This is a striking finding — most obesity drugs show diminishing returns by this timepoint.
How This Compares to Current Options
To put these numbers in perspective, here's how retatrutide stacks up against medications currently available in Malaysia:
- Saxenda (liraglutide): ~8% weight loss — available in Malaysia
- Ozempic (semaglutide 1 mg): ~12-15% weight loss — available in Malaysia
- Wegovy (semaglutide 2.4 mg): ~15-17% weight loss — available in Malaysia
- Mounjaro (tirzepatide): ~20-22.5% weight loss — available in Malaysia
- Retatrutide: ~24.2% weight loss — not yet approved
- Bariatric surgery (Roux-en-Y): ~25-35% weight loss
Retatrutide is the first medication to genuinely approach bariatric surgery territory. For more detailed comparisons, see our articles on retatrutide vs semaglutide and retatrutide vs tirzepatide.
Phase 3 TRIUMPH Trials: What We Know
Eli Lilly launched the Phase 3 clinical programme in 2024 under the name TRIUMPH. This is one of the most ambitious obesity drug development programmes ever conducted, spanning five separate trials:
| Trial | Indication | Status |
|---|---|---|
| TRIUMPH-1 | Obesity/overweight (non-diabetic) | Enrolling / ongoing |
| TRIUMPH-2 | Obesity with type 2 diabetes | Enrolling / ongoing |
| TRIUMPH-3 | Cardiovascular outcomes (MACE) | Enrolling / ongoing |
| TRIUMPH-4 | MASH (fatty liver disease) | Enrolling / ongoing |
| TRIUMPH-5 | Obstructive sleep apnoea | Enrolling / ongoing |
Initial data readouts from TRIUMPH-1 and TRIUMPH-2 are anticipated in late 2026 to early 2027. The cardiovascular outcomes trial (TRIUMPH-3) will take longer, likely reporting in 2028–2029.
What to Expect from Phase 3 Results
Phase 3 trials typically enroll thousands of patients (vs hundreds in Phase 2) across more diverse populations. It's common for Phase 3 results to be slightly more conservative than Phase 2 — a more realistic expectation for retatrutide's Phase 3 weight loss is 20–25%, which would still be best-in-class by a significant margin.
When Will Retatrutide Be Available in Malaysia?
This is the question every Malaysian patient is asking. Here's our best estimate based on the regulatory pathway:
| Milestone | Estimated Timeline |
|---|---|
| Phase 3 data readout | Late 2026 – Early 2027 |
| FDA submission (US) | Mid-to-Late 2027 |
| FDA approval | Late 2027 – Early 2028 |
| EMA approval (Europe) | 2028 |
| NPRA submission (Malaysia) | 2028–2029 |
| NPRA approval | 2029 (optimistic) – 2030 |
| Clinic availability in Malaysia | 2029–2030 |
Malaysia's National Pharmaceutical Regulatory Agency (NPRA) has historically been reasonably efficient at reviewing drugs that already have FDA and/or EMA approval. Eli Lilly also has established distribution infrastructure in Malaysia through its existing Mounjaro (tirzepatide) presence, which could accelerate the launch.
An encouraging precedent: Mounjaro received NPRA registration within approximately 12–18 months of FDA approval. If retatrutide follows a similar trajectory, Malaysian patients could have access by 2029.
Projected Retatrutide Price in Malaysia
Since retatrutide is not yet approved, pricing remains speculative. However, we can make reasonable projections based on Eli Lilly's pricing strategy for Mounjaro and the broader market dynamics:
Price Projection Based on Current Market
| Drug | Mechanism | Malaysia Price (RM/month) |
|---|---|---|
| Saxenda (liraglutide) | GLP-1 (daily) | RM1,200–1,800 |
| Ozempic (semaglutide) | GLP-1 (weekly) | RM800–1,800 |
| Mounjaro (tirzepatide) | GLP-1 + GIP (weekly) | RM1,088–3,000 |
| Retatrutide (projected) | GLP-1 + GIP + Glucagon | RM2,500–4,500 |
Several factors will influence the actual price:
- Premium positioning: As a next-generation, best-in-class drug, Eli Lilly will likely price retatrutide above Mounjaro
- Competition: By 2029–2030, the market will include multiple effective options, which could moderate pricing
- Manufacturing scale: Peptide manufacturing costs have been declining, and Eli Lilly has invested heavily in production capacity
- Insurance coverage: Most Malaysian private insurance plans do not currently cover weight loss medications, though this may evolve as clinical evidence grows
For a regularly updated comparison of current medication costs, see our Weight Loss Injection Prices Malaysia guide.
Side Effects: What the Phase 2 Data Showed
Retatrutide's side effect profile in Phase 2 was broadly similar to existing GLP-1 medications, with some nuances from the glucagon component. For a deep dive, see our dedicated retatrutide side effects guide.
Most Common Side Effects
- Nausea: ~25% of participants (mostly during dose escalation)
- Diarrhoea: Slightly more common than with semaglutide alone
- Vomiting: ~10-15% at higher doses
- Constipation
- Decreased appetite (often considered a therapeutic effect rather than a side effect)
Glucagon-Specific Considerations
- Modest heart rate increase: Consistent with glucagon's stimulatory effects, though not clinically significant in Phase 2
- Blood glucose balance: Despite glucagon raising blood sugar, the GLP-1/GIP components more than compensate — glucose control improved overall
The overall discontinuation rate due to adverse events was low and comparable to tirzepatide trials. Phase 3 data with thousands of participants will provide a definitive safety profile.
Retatrutide vs Bariatric Surgery
With retatrutide producing ~24% weight loss in Phase 2, the comparison to bariatric surgery is now clinically meaningful:
| Factor | Retatrutide | Bariatric Surgery |
|---|---|---|
| Weight loss | ~24% (Phase 2) | ~25–35% |
| Method | Weekly injection | Major surgery |
| Reversibility | Fully reversible | Largely irreversible |
| Recovery | None | 2–6 weeks |
| Cost (Malaysia) | ~RM2,500–4,500/month ongoing | RM25,000–60,000 one-time |
| Weight regain risk | Likely if stopped | 20–30% regain common |
| Nutritional deficiency | Low | Significant (lifelong supplements) |
| Availability | 2029–2030 (Malaysia) | Available now |
For patients with BMI 35–45, retatrutide could become a compelling non-surgical alternative. For BMI >50, bariatric surgery may still be preferred. The choice will ultimately depend on individual patient factors, preferences, and the Phase 3 data.
How Retatrutide Differs from Ozempic and Mounjaro
For Malaysian patients already on or considering GLP-1 medications, here's how retatrutide fits into the landscape:
- vs Ozempic: Retatrutide targets 3 receptors vs Ozempic's 1. In trials, it produces roughly 60% more weight loss. Full comparison: Retatrutide vs Semaglutide
- vs Mounjaro: Both from Eli Lilly. Retatrutide adds glucagon receptor agonism on top of Mounjaro's dual mechanism, yielding an additional ~2-5% weight loss. Full comparison: Retatrutide vs Tirzepatide
- vs Wegovy: Wegovy (semaglutide 2.4 mg) is the approved weight-management version of Ozempic. Retatrutide still significantly outperforms it in head-to-head trial comparisons
The Broader Pipeline: What Else Is Coming
Retatrutide isn't the only next-generation obesity drug in development. The pipeline is extraordinarily active:
- Orforglipron (Eli Lilly): An oral GLP-1 agonist — a daily pill rather than injection. Phase 3 ongoing. Could dramatically improve access and convenience
- Survodutide (Boehringer Ingelheim): Dual GLP-1/glucagon agonist showing ~19% weight loss in Phase 2
- Amycretin (Novo Nordisk): Dual amylin/GLP-1 agonist with early data showing ~13% loss in just 12 weeks
- CagriSema (Novo Nordisk): Cagrilintide + semaglutide combination, ~22.7% weight loss in trials
By 2030, Malaysian patients will likely have access to 5–8 different effective weight management medications across various mechanisms, price points, and administration routes (injections, pills, and potentially implants).
What Malaysian Patients Should Do Now
Retatrutide is still years away from Malaysian pharmacy shelves. Here's practical guidance:
If You're Currently Overweight or Obese
- Don't wait for retatrutide. Current medications are already highly effective. Ozempic and Mounjaro are available now and produce significant weight loss
- Consult a weight management specialist. Clinics in KL, Penang, and Johor Bahru offer comprehensive metabolic health assessments. See our guide to weight loss clinics in KL
- Build foundational habits. Regardless of which medication you use, nutrition and exercise form the foundation of long-term success
- Consider your options carefully. Our Mounjaro vs Ozempic comparison can help you decide what's right for you today
If You're Interested in Clinical Trials
Eli Lilly's TRIUMPH programme includes trial sites across Asia. Check ClinicalTrials.gov for active sites near you, or ask your endocrinologist about eligibility. Participating in a clinical trial gives you early access to the medication under medical supervision at no cost.
What to Avoid
Do not purchase "retatrutide" from online sellers, compounding pharmacies, or grey-market sources. The drug is not commercially manufactured yet. Any product sold as retatrutide is either counterfeit, a different substance, or a research-grade chemical not intended for human use. The risks — contamination, incorrect dosing, dangerous impurities — are real and serious.
Frequently Asked Questions
Is retatrutide approved in Malaysia?
No. As of February 2026, retatrutide is not approved by any regulatory authority worldwide. It remains in Phase 3 clinical trials.
What's the expected price for retatrutide in Malaysia?
Based on Mounjaro's pricing trajectory, we project RM2,500–4,500 per month at launch. Actual pricing will depend on Eli Lilly's strategy, competition, and NPRA negotiations.
Will retatrutide work better than Mounjaro?
Phase 2 data suggests a modest improvement over tirzepatide (~24% vs ~22% weight loss), with the additional benefit of increased energy expenditure from the glucagon component. Phase 3 head-to-head data will provide a definitive answer.
Can I switch from Ozempic to retatrutide when it's available?
This will be a clinical decision made with your doctor. In principle, switching between GLP-1-based medications is feasible, but the specific titration protocol and transition approach for retatrutide will be established during Phase 3 trials and included in the prescribing information.
Is retatrutide safe?
Phase 2 data showed an acceptable safety profile similar to existing GLP-1 drugs. However, Phase 3 trials with thousands of patients are needed to fully characterise the safety profile, including rare adverse events. This is exactly why the regulatory process exists — and why you should not use unapproved versions of this drug.
The Bottom Line
Retatrutide represents the next frontier in obesity pharmacotherapy. Its triple mechanism of action — targeting GLP-1, GIP, and glucagon receptors simultaneously — produces weight loss approaching bariatric surgery levels, with the convenience of a weekly injection.
For Malaysian patients, the realistic availability timeline is 2029–2030. In the meantime, excellent options exist today: Ozempic, Mounjaro, and Wegovy are all available and producing life-changing results for thousands of Malaysians.
We'll continue updating this guide as Phase 3 TRIUMPH data emerges and regulatory timelines become clearer. Bookmark this page and check back regularly.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any treatment, supplement regimen, or making changes to your health routine. Individual results may vary, and what works for others may not work for you.